The sharp gross margin expansion appears to be a product mix effect, likely from higher-margin segments like Scent and Health & Biosciences, rather than broad-based pricing power. Operating margin at 8.1% is still below the 10.2% seen in 2026Q1, indicating that SG&A and other operating costs are absorbing the gross margin gains. Net margin of 2.6% in 2026Q2 is a recovery from the -35.8% in 2025Q1, but the volatility underscores the impact of non-recurring items and interest burden. Investors should monitor whether the gross margin can hold above 40% as revenue continues to decline, which would signal a structural shift toward higher-value products.

ROIC of 0.6% in 2026Q2 is a marginal improvement from 0.4% in 2025Q4, but it remains negligible relative to the capital employed. The DuPont N&B acquisition appears to have loaded the balance sheet with goodwill and intangibles, which inflate the capital base and depress returns. Even as debt is reduced, the return on capital is not recovering, suggesting that the underlying business is not generating sufficient operating profit to cover its capital costs. This implies that the market's forward P/E of 23.5x is pricing in a significant margin recovery that has yet to materialize in the return metrics.

The 40-day increase in DIO is a red flag, as it suggests that IFF is building inventory ahead of expected sales that have not materialized, given the -5.2% YoY revenue decline. DSO also rose to 89 days from 66 days, indicating slower collections, which may reflect customer destocking or weaker negotiating power. DPO at 101 days is relatively stable, but the overall CCC expansion ties up cash and pressures free cash flow. This inefficiency is particularly concerning because the company is trying to deleverage; the working capital build could be consuming cash that would otherwise go toward debt reduction.

The improvement in interest coverage is welcome, but it is still low for an investment-grade company, and the D/EBITDA ratio is distorted by depressed EBITDA. The reported D/E of 0.45 understates leverage because goodwill of $8.1B inflates equity; on a tangible basis, leverage is much higher. The company has been selling assets to reduce debt, but the divestiture of Pharma Solutions removes a high-margin cash flow stream, which could weaken coverage further. Investors should monitor whether the deleveraging trajectory can continue without impairing the company's ability to invest in growth.

The current ratio is healthy, but the quick ratio of 1.72 indicates that inventory is a significant component of current assets, which may be less liquid in a downturn. The cash balance is small relative to the company's debt load, and the reliance on asset sales to fund operations is a concern. In a severe demand shock, the company might need to draw on credit lines or further divest assets, which could be at unfavorable prices. The liquidity position appears adequate for the near term, but it does not provide a wide margin of safety.